Wire · opportunities
FDA panel gives nod to six controversial peptides
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 July 2026 · Fusion42 review
An FDA advisory panel voted to recommend loosening regulations on six peptide treatments (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500), allowing compounding pharmacies to produce them for prescription use rather than unregulated online vendors. The FDA will make a final decision after the committee's recommendation, though agency scientists have raised concerns about insufficient safety and efficacy data.
This Wire brief sits within Fusion42's coverage of Digital Health, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
If you make peptides or supply compounding pharmacies, the FDA just opened a regulated market for six compounds that were only available through grey-market vendors. The final decision takes months, but the advisory vote signals where this is heading—call your compounding pharmacy customers now.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics